AR045576A1 - Composicion farmaceutica que comprende drospirenona y etinilestradiol - Google Patents
Composicion farmaceutica que comprende drospirenona y etinilestradiolInfo
- Publication number
- AR045576A1 AR045576A1 ARP040103168A ARP040103168A AR045576A1 AR 045576 A1 AR045576 A1 AR 045576A1 AR P040103168 A ARP040103168 A AR P040103168A AR P040103168 A ARP040103168 A AR P040103168A AR 045576 A1 AR045576 A1 AR 045576A1
- Authority
- AR
- Argentina
- Prior art keywords
- drospirenone
- pharmaceutical composition
- therapeutically inert
- estradiol
- absorbed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Una composición farmacéutica que comprende drospirenona y etinilestradiol con una mejorada velocidad de disolución. Un método de preparación de una formulación farmacéutica que comprende drospirenona y etinilestradiol a fin de mejorar su perfil de disolución. Dicha formulación puede ser utilizada para producir un efecto anovulatorio cuando es administrada correctamente en humanos. Reivindicación 1: Una composición farmacéutica que comprende drospirenona y etinilestradiol en forma amorfa, absorbidos sobre un soporte sólido terapéuticamente inerte, en combinación con excipientes farmacéuticamente aceptables. Reivindicación 5: Un procedimiento para preparar la composición farmacéutica de acuerdo con cualquiera de las reivindicaciones anteriores, caracterizado porque comprende: i) disolver drospirenona y etinilestradiol en un solvente volátil o mezcla de solventes volátiles, ii) agregar un polímero soluble en agua, iii) mezclar hasta disolución; iv) aplicar la solución resultante sobre un soporte de partículas sólido, terapéuticamente inerte, y v) secar el adsorbato granulado obtenido. Reivindicación 13: Una preparación farmacéutica que consiste en un número unidades de dosis para suministro oral diario por un período de al menos 21 días consecutivos, donde dichas unidades de dosis comprenden aproximadamente desde 1 mg a 4 mg de drospirenona y aproximadamente desde 0,01 a 0,05 mg de etinilestradiol, caracterizada porque dichos drospirenona y etinilestradiol están en forma amorfa, absorbidos sobre un soporte sólido terapéuticamente inerte, de cualquiera de las reivindicaciones 1 a 4, en combinación con excipientes farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04103837A EP1625849A1 (en) | 2004-08-09 | 2004-08-09 | Pharmaceutical composition comprising drospirenone and ethynylestradiol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR045576A1 true AR045576A1 (es) | 2005-11-02 |
Family
ID=34929434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040103168A AR045576A1 (es) | 2004-08-09 | 2004-09-03 | Composicion farmaceutica que comprende drospirenona y etinilestradiol |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20090227546A1 (es) |
| EP (2) | EP1625849A1 (es) |
| JP (1) | JP2008509195A (es) |
| KR (1) | KR20070045247A (es) |
| CN (1) | CN101022811B (es) |
| AR (1) | AR045576A1 (es) |
| AT (1) | ATE464053T1 (es) |
| AU (1) | AU2005271206B2 (es) |
| BR (1) | BRPI0513938B8 (es) |
| CA (1) | CA2574997A1 (es) |
| DE (1) | DE602005020694D1 (es) |
| ES (1) | ES2344356T3 (es) |
| IL (1) | IL180899A0 (es) |
| MA (1) | MA28844B1 (es) |
| NO (1) | NO20071297L (es) |
| RU (1) | RU2007108666A (es) |
| UA (1) | UA87513C2 (es) |
| WO (1) | WO2006015956A1 (es) |
| ZA (1) | ZA200702038B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2531929T3 (es) * | 2006-12-20 | 2015-03-20 | Teva Women's Health, Inc. | Formas de dosificación solidas que se disgregan en la boca que comprenden progestina y métodos para hacer y usar las mismas |
| HUP0700826A3 (en) | 2007-12-20 | 2010-03-29 | Richter Gedeon Nyrt | Coated tablet containing drospirenone and process for producing the same |
| DE102008037025C5 (de) | 2008-08-08 | 2016-07-07 | Jesalis Pharma Gmbh | Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform |
| KR102023255B1 (ko) | 2009-04-01 | 2019-09-19 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법 |
| JP5864410B2 (ja) * | 2009-04-01 | 2016-02-17 | ノヴィファーマ ソシエテ アノニム | ニトロカテコール誘導体を含む医薬製剤及びその製造方法 |
| US10849857B2 (en) * | 2010-07-28 | 2020-12-01 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
| US11351122B1 (en) | 2010-07-28 | 2022-06-07 | Laboratorios Leon Farma Sa | Synthetic progestogens and pharmaceutical compositions comprising the same |
| AR081670A1 (es) | 2010-06-29 | 2012-10-10 | Leon Farma Sa Lab | Composicion farmaceutica que comprende drospirenona y kit anticonceptivo |
| US9603860B2 (en) * | 2010-07-28 | 2017-03-28 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
| US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| CN102274235B (zh) * | 2011-06-27 | 2013-03-13 | 潍坊中狮制药有限公司 | 一种新的避孕药物组合及制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| FR2722984B1 (fr) * | 1994-07-26 | 1996-10-18 | Effik Lab | Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees |
| US6027747A (en) * | 1997-11-11 | 2000-02-22 | Terracol; Didier | Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions |
| EP1598069B1 (en) * | 1999-08-31 | 2009-04-22 | Bayer Schering Pharma Aktiengesellschaft | Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive |
| EE05317B1 (et) * | 1999-08-31 | 2010-08-16 | Bayer Schering Pharma Aktiengesellschaft | Etinlstradiooli ja drospirenooni sisaldav farmatseutiline kompositsioon kasutamiseks rasestumisvastase vahendina |
| DK1361881T3 (da) * | 2000-12-14 | 2006-02-20 | Ortho Mcneil Pharm Inc | Steroide hormonprodukter og fremgangsmåder til fremstilling heraf |
| EP1216712A1 (en) * | 2000-12-20 | 2002-06-26 | Schering Aktiengesellschaft | Cyclodextrin-drospirenone inclusion complexes |
-
2004
- 2004-08-09 EP EP04103837A patent/EP1625849A1/en not_active Withdrawn
- 2004-09-03 AR ARP040103168A patent/AR045576A1/es not_active Application Discontinuation
-
2005
- 2005-08-02 DE DE602005020694T patent/DE602005020694D1/de not_active Expired - Lifetime
- 2005-08-02 AU AU2005271206A patent/AU2005271206B2/en not_active Ceased
- 2005-08-02 US US11/573,499 patent/US20090227546A1/en not_active Abandoned
- 2005-08-02 CN CN2005800271055A patent/CN101022811B/zh not_active Expired - Fee Related
- 2005-08-02 ES ES05777862T patent/ES2344356T3/es not_active Expired - Lifetime
- 2005-08-02 JP JP2007525283A patent/JP2008509195A/ja not_active Withdrawn
- 2005-08-02 WO PCT/EP2005/053759 patent/WO2006015956A1/en not_active Ceased
- 2005-08-02 KR KR1020077003265A patent/KR20070045247A/ko not_active Withdrawn
- 2005-08-02 CA CA002574997A patent/CA2574997A1/en not_active Abandoned
- 2005-08-02 RU RU2007108666/15A patent/RU2007108666A/ru not_active Application Discontinuation
- 2005-08-02 AT AT05777862T patent/ATE464053T1/de not_active IP Right Cessation
- 2005-08-02 EP EP05777862A patent/EP1848441B1/en not_active Revoked
- 2005-08-02 ZA ZA200702038A patent/ZA200702038B/xx unknown
- 2005-08-02 BR BRPI0513938A patent/BRPI0513938B8/pt active IP Right Grant
- 2005-08-02 UA UAA200702482A patent/UA87513C2/ru unknown
-
2007
- 2007-01-23 IL IL180899A patent/IL180899A0/en unknown
- 2007-03-02 MA MA29728A patent/MA28844B1/fr unknown
- 2007-03-09 NO NO20071297A patent/NO20071297L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE464053T1 (de) | 2010-04-15 |
| AU2005271206B2 (en) | 2009-11-26 |
| KR20070045247A (ko) | 2007-05-02 |
| RU2007108666A (ru) | 2008-09-20 |
| DE602005020694D1 (de) | 2010-05-27 |
| EP1625849A1 (en) | 2006-02-15 |
| BRPI0513938B1 (pt) | 2018-09-25 |
| BRPI0513938B8 (pt) | 2021-05-25 |
| CN101022811A (zh) | 2007-08-22 |
| EP1848441A1 (en) | 2007-10-31 |
| JP2008509195A (ja) | 2008-03-27 |
| ES2344356T3 (es) | 2010-08-25 |
| ZA200702038B (en) | 2008-08-27 |
| NO20071297L (no) | 2007-05-02 |
| BRPI0513938A (pt) | 2008-05-20 |
| CN101022811B (zh) | 2010-09-15 |
| UA87513C2 (ru) | 2009-07-27 |
| AU2005271206A1 (en) | 2006-02-16 |
| EP1848441B1 (en) | 2010-04-14 |
| HK1109579A1 (en) | 2008-06-13 |
| WO2006015956A1 (en) | 2006-02-16 |
| MA28844B1 (fr) | 2007-09-03 |
| US20090227546A1 (en) | 2009-09-10 |
| CA2574997A1 (en) | 2006-02-16 |
| IL180899A0 (en) | 2007-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2655705T3 (es) | Composición que comprende rotigotina, su uso y parche transdérmico que comprende la composición | |
| ES2283425T3 (es) | Nueva composicion para la administracion transdermica y/o transmucosa de compuestos activos que asegura niveles terapeutiocos adecuados. | |
| US9610253B2 (en) | Transdermal administration of tamsulosin | |
| MX2008000099A (es) | Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones. | |
| BRPI0015567B8 (pt) | composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica | |
| JP2005512995A5 (es) | ||
| AR039744A1 (es) | Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada | |
| BR9808888A (pt) | Formas de dosagem e método de melhorar disfunção erétil masculina | |
| HRP20050077B1 (hr) | Postupci i oblici doziranja za kontrolirano oslobađanje paliperidona | |
| MXPA04003608A (es) | Composiciones inyectables para el suministro controlado de compuesto farmacologicamente activo. | |
| AR040722A1 (es) | Formulaciones y formas de dosificacion para la administracion controlada de topiramato | |
| WO2002053100A3 (en) | Pharmaceutical dosage form for oral administration of low molecular weight heparin | |
| BRPI0512177A (pt) | formulação de liberação modificada de memantina | |
| AR037642A1 (es) | Preformulacion farmaceutica para tabletado, y procedimiento para su preparacion | |
| JP2004507496A5 (es) | ||
| BR0007360A (pt) | Composição de liberação controlada | |
| Li et al. | Improvement of the dissolution rate of silymarin by means of solid dispersions | |
| WO2004110445A1 (ja) | フェンタニル含有口腔粘膜貼付剤 | |
| SE9603480D0 (sv) | Beredningsform för svårlösliga läkemedel | |
| ME02149B (me) | FORMULACIJE l METODE ZA LEČENJE AMILOIDOZE | |
| BRPI0413883A (pt) | composição e método para a administração de um composto farmacologicamente ativo a um mamìfero | |
| WO2004091541A3 (en) | Methods for the controlled delivery of pharmacologically active compounds | |
| ES2171110A1 (es) | Composicion farmaceutica a base de ibuprofeno y procedimiento para su preparacion. | |
| Yong et al. | Enhanced anti-tumor activity and alleviated hepatotoxicity of clotrimazole-loaded suppository using poloxamer–propylene glycol gel | |
| BRPI0506710A (pt) | composições farmacêuticas de liberação controlada |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |